Literature DB >> 25217709

Comparison of genomic abnormality in malignant mesothelioma by the site of origin.

Maiko Takeda1, Takahiko Kasai2, Yasunori Enomoto1, Masato Takano1, Kohei Morita1, Tokiko Nakai1, Norishige Iizuka3, Hiroshi Maruyama4, Chiho Ohbayashi1.   

Abstract

AIMS: Malignant mesothelioma (MM) results from the accumulation of a number of acquired genetic events at the onset. In MM, the most frequent changes are losses in 9p21, 1p36, 22q12 and 14q32, and gains in 5p, 7p and 8q24 by comparative genomic hybridisation analysis. We have examined various genomic losses and gains in MM and benign mesothelial proliferation by fluorescence in situ hybridisation (FISH) analysis. 9p21 deletion was reported to be less frequent in peritoneal than in pleural MMs. This study analysed various genomic losses and gains in MM by the site of origin using FISH analysis.
MATERIALS AND METHODS: We performed FISH analysis using paraffin-embedded tissues from 54 cases (40 pleural and 14 peritoneal) of MMs and compared the frequency of genomic abnormality by the site of origin.
RESULTS: 9p21 deletion was shown in 34 of 40 cases (85%) of pleural MMs, and was less frequent in five of 14 cases (36%) of peritoneal MMs (p<0.001) by FISH analysis. By contrast, 5p15 and 7p12 amplification was more significantly frequent in peritoneal than in pleural MMs. No difference between the two sites of MM in other genes was found.
CONCLUSIONS: 9p21 homozygous deletion assessed by FISH has been reported to be useful for differentiating MM from reactive mesothelial proliferation, but it should be noted that 9p21 deletion was less frequent in peritoneal MM. Our study suggests that the pathway of the genetic abnormality might vary between pleural and peritoneal MM. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  FISH; MALIGNANT TUMOURS; MOLECULAR PATHOLOGY; PERITONEUM; PLEURA

Mesh:

Substances:

Year:  2014        PMID: 25217709     DOI: 10.1136/jclinpath-2014-202465

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

Review 1.  [The German Mesothelioma Register : Current pathological diagnostics and services].

Authors:  I S Feder; M Jülich; A Tannapfel; I Tischoff
Journal:  Pathologe       Date:  2018-12       Impact factor: 1.011

2.  [Mesothelioma].

Authors:  I Tischoff; A Tannapfel
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

3.  TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways.

Authors:  Yuhui Wang; Nan Wu; Bo Pang; Dandan Tong; Donglin Sun; Haiming Sun; Chunyu Zhang; Wenjing Sun; Xiangning Meng; Jing Bai; Feng Chen; Jingshu Geng; Songbin Fu; Yan Jin
Journal:  Oncotarget       Date:  2017-07-18

4.  Peritoneal Mesothelioma with Residential Asbestos Exposure. Report of a Case with Long Survival (Seventeen Years) Analyzed by Cgh-Array.

Authors:  Gabriella Serio; Federica Pezzuto; Andrea Marzullo; Anna Scattone; Domenica Cavone; Alessandra Punzi; Francesco Fortarezza; Mattia Gentile; Antonia Lucia Buonadonna; Mattia Barbareschi; Luigi Vimercati
Journal:  Int J Mol Sci       Date:  2017-08-22       Impact factor: 5.923

5.  Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.

Authors:  Nancy M Joseph; Yunn-Yi Chen; Anthony Nasr; Iwei Yeh; Eric Talevich; Courtney Onodera; Boris C Bastian; Joseph T Rabban; Karuna Garg; Charles Zaloudek; David A Solomon
Journal:  Mod Pathol       Date:  2016-11-04       Impact factor: 7.842

6.  Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.

Authors:  Rocco Sciarrillo; Anna Wojtuszkiewicz; Btissame El Hassouni; Niccola Funel; Paolo Gandellini; Tonny Lagerweij; Silvia Buonamici; Maxime Blijlevens; Eveline A Zeeuw van der Laan; Nadia Zaffaroni; Marcello Deraco; Shigeki Kusamura; Tom Würdinger; Godefridus J Peters; Carla F M Molthoff; Gerrit Jansen; Gertjan J L Kaspers; Jacqueline Cloos; Elisa Giovannetti
Journal:  EBioMedicine       Date:  2018-12-20       Impact factor: 8.143

7.  Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study.

Authors:  Rui Kitadai; Tatsunori Shimoi; Kazuki Sudo; Emi Noguchi; Yusuke Nagata; Ryoichi Sawada; Atsuo Takashima; Narikazu Boku; Kan Yonemori
Journal:  BMC Cancer       Date:  2021-03-20       Impact factor: 4.430

8.  Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma?

Authors:  Tomas Mickevicius; Alvita Vilkeviciute; Brigita Glebauskiene; Loresa Kriauciuniene; Rasa Liutkeviciene
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

9.  Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.

Authors:  Gauri R Varadhachary; Daniel M Halperin; Kanwal Raghav; Suyu Liu; Michael J Overman; Anneleis F Willett; Mark Knafl; Szu-Chin Fu; Anais Malpica; Seema Prasad; Richard E Royal; Christopher P Scally; Paul F Mansfield; Ignacio I Wistuba; Andrew P Futreal; Dipen M Maru; Luisa M Solis Soto; Edwin R Parra Cuentas; Honglei Chen; Pamela Villalobos; Anuj Verma; Armeen Mahvash; Patrick Hwu; Patricia Cortazar; Edward McKenna; Cindy Yun; Shannon Dervin; Katja Schulze; Walter C Darbonne; Ajaykumar C Morani; Scott Kopetz; Keith F Fournier; Scott E Woodman; James C Yao
Journal:  Cancer Discov       Date:  2021-07-14       Impact factor: 39.397

Review 10.  Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Authors:  Stergios Boussios; Michele Moschetta; Afroditi Karathanasi; Alexandros K Tsiouris; Foivos S Kanellos; Konstantina Tatsi; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2018-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.